Griseofulvin Shortage: What Providers and Prescribers Need to Know in 2026

While griseofulvin does not appear on the FDA's active Drug Shortage Database as of 2026, prescribers are hearing from patients who can't fill their prescriptions. The issue is structural: griseofulvin is a low-volume generic with complex formulation requirements, and many retail pharmacies simply don't stock it reliably. This is particularly problematic for pediatric patients requiring the oral suspension and for families in areas with limited pharmacy access. This guide covers the current availability landscape, clinical decision-making for alternatives, and practical strategies to help your patients.

Current Availability Status (2026)

Griseofulvin is not currently on the FDA Drug Shortages list. However, availability is uneven across the US:

Tablets (microsize 500 mg): Generally available at larger pharmacy chains and independent pharmacies that routinely stock specialty generics.

Ultramicrosize tablets (125 mg, 250 mg): Available at many pharmacies but require verification of stock before sending a prescription.

Oral suspension (125 mg/5 mL): Frequently unavailable at retail chains. Pediatric pharmacies, children's hospital outpatient pharmacies, and compounding pharmacies are the most reliable sources.

Clinical Context: Who Is Being Prescribed Griseofulvin?

The majority of griseofulvin prescriptions in the US fall into three categories:

Pediatric tinea capitis: Griseofulvin remains first-line in US guidelines for tinea capitis in children. Treatment is 6–12 weeks with microsize (20–25 mg/kg/day) or the equivalent ultramicrosize dose. The oral suspension is preferred for young children who cannot swallow tablets.

Onychomycosis: Though largely replaced by terbinafine and itraconazole, griseofulvin is still prescribed for nail fungal infections when newer agents are contraindicated or unavailable. Treatment duration is 6–18 months, making continuous access critical.

Superficial dermatophytoses resistant to topical treatment: Extensive tinea corporis, tinea pedis, or tinea cruris that has not responded to topical antifungals may be treated with oral griseofulvin.

Evidence-Based Alternatives by Indication

Tinea capitis:

Terbinafine (Lamisil): Preferred alternative for Trichophyton tonsurans infections (the most common causative agent in the US). Typical dose: 62.5–250 mg/day for 2–4 weeks depending on weight. Less effective than griseofulvin for Microsporum canis infections.

Itraconazole: 5 mg/kg/day for 4–6 weeks; effective for both Trichophyton and Microsporum species; not available as a suspension for young children.

Fluconazole: 6 mg/kg/week for 8–16 weeks (off-label); available as a liquid; generally less efficacious but may be appropriate when other options are unavailable.

Onychomycosis:

Terbinafine: First-line alternative; 250 mg/day for 6 weeks (fingernails) or 12 weeks (toenails). Superior mycological cure rates compared to griseofulvin.

Itraconazole: 200 mg daily for 6–12 weeks or pulse dosing (400 mg/day for 1 week per month); preferred for non-dermatophyte mold infections.

Key Drug Interactions to Consider When Switching

Griseofulvin is a CYP3A4 inducer. Switching to itraconazole or fluconazole — both CYP3A4 inhibitors — requires careful review of concomitant medications. Patients on anticoagulants, immunosuppressants, or certain antiretrovirals may experience clinically significant drug-level changes.

Terbinafine is a CYP2D6 inhibitor and has fewer CYP3A4 interactions, making it a pharmacokinetically cleaner switch from griseofulvin for most patients. However, it carries a small risk of hepatotoxicity — baseline LFTs should be considered for patients on prolonged therapy.

Practical Strategies for Your Practice

Pre-check pharmacy stock before sending the e-prescription: Ask staff to call ahead or use medfinder's provider tool to check local pharmacy availability before the patient leaves.

Note acceptable formulation substitutions on the prescription: Indicate "microsize or ultramicrosize acceptable" on the prescription to give pharmacists flexibility.

Establish a relationship with a local compounding pharmacy: For pediatric patients, having a go-to compounding pharmacy for the suspension can save significant time when retail pharmacies are out of stock.

Educate patients proactively: Set expectations that griseofulvin may not be at their usual pharmacy and suggest they call ahead or use a pharmacy-finding service before heading there.

How medfinder Helps Your Patients

medfinder is a service that calls pharmacies near patients to check which ones have a specific medication in stock, then texts patients the results. For patients struggling to locate griseofulvin — particularly the oral suspension — this can save hours and prevent dangerous treatment delays. Learn how medfinder supports providers here.